Nestlé S.A.

Nestlé reported H1 2026 organic sales growth of 3.6%, with RIG of 1.5% and pricing of 2.1%. Q1 RIG was 1.2% and Q2 RIG was 1.8%; Q2 all-category RIG was positive. UTOP margin was 16.4% in H1, down 10 bps year over year, and underlying EPS rose 4% in constant currency but fell 2.4% at actual exchange rates due to the Swiss franc. Free cash flow was CHF 3.4 billion, net debt was CHF 56.3 billion, and H1 cost savings were CHF 600 million, bringing cumulative savings to CHF 1.7 billion. For 2026, management tightened organic growth guidance to 3% to 4% (from around 3% to 4%), kept the full-year UTOP margin outlook for improvement versus 2025, expects H2 margin to be broadly similar to H1, and continues to expect free cash flow above CHF 9 billion.

Philipp Navratil emphasized that execution is improving and that growth is being driven by better RIG across the business. He framed the strategy around a sharpened portfolio, with a focus on four large categories and a more deliberate allocation of resources to core versus growth platforms, while also highlighting a cultural shift toward faster decisions and a stronger performance culture. His tone was upbeat but disciplined: the company is making progress, but he repeatedly said the main task is consistent execution quarter after quarter.

Anna Manz said H1 results benefited from improving RIG, cost savings slightly ahead of plan, and stronger cash generation, despite headwinds from higher input costs, tariffs, FX, and the infant formula recall. She noted H1 UTOP margin of 16.4%, H1 free cash flow of CHF 3.4 billion, net debt of CHF 56.3 billion, and CHF 600 million of incremental savings in the half, with cumulative savings at CHF 1.7 billion toward CHF 2 billion by end-2026 and CHF 3 billion by end-2027. She also said marketing spend rose to 8.9% of sales, H2 margin should be broadly similar to H1, and the company still expects free cash flow above CHF 9 billion for the year.

Analysts focused on PetCare destocking, whether North American inventory reductions would continue, and how to think about H2/H2027 margin progression. Management said U.S. PetCare weakness was driven by one-off retailer inventory reductions as supply normalized, and that underlying sell-out is improving; they do not expect further major inventory issues. Questions also centered on coffee pricing and Nespresso, where management said pricing is staggered rather than late, there was no Q1 prebuy, and Nespresso growth is still being driven mainly by Vertuo and household penetration in North America. Analysts also pressed on AOA strength, European delistings, and the margin bridge; management said the Europe delisting was a phasing issue in a single customer and that the margin bridge included multiple items beyond infant formula, with a 30 bps pension benefit that had no ongoing P&L impact.